Full-Time

QC Data Reviewer III

Posted on 5/15/2024

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Entry, Junior

Bridgewater Township, NJ, USA

100% onsite at the Raritan, NJ location.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in science, Engineering or equivalent technical discipline is required.
  • Minimum of 1-year relevant work experience, preferably within a biological and/or pharmaceutical industry is required.
  • Knowledge of cGMP and GDP regulations and FDA/EU guidance related to manufacturing of cell-based products is required.
  • Excellent written and oral communication skill are required.
  • Candidates must be able to accommodate shift schedule. Shifts include routine weekend and evening work as required by the manufacturing process.
  • Candidates must be able to accommodate unplanned overtime (including nights and weekends) on little to no prior notice.
  • The candidate must be highly organized and capable of working in a team environment with a positive attitude under some supervision.
  • Comfortable with speaking and interacting with inspectors.
  • Due to the nature of the Data Review process, this role is 100% onsite at the Raritan, NJ location.
Responsibilities
  • Perform peer review/approval of laboratory data including but not limited to eLIMS Electronic Notebooks, laboratory formbooks, training formbooks, instrument logbooks, and records.
  • Utilization of electronic systems (LIMS) for execution and documentation.
  • Create, review, and approve relevant QC documents, SOP’s and WI’s.
  • Perform tasks in a manner consistent with the safety policies, quality systems and cGMP requirements.
  • Immediately alerts supervisor/manager when data discrepancies are identified.
  • Job duties performed may occasionally require exposure to and handling of biological materials and hazardous chemicals.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
  • New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
  • Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

What critics are saying

  • Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
  • Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
  • Financial strain from new R&D facility could affect operational focus if advancements lag.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

INACTIVE